Showing 672 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

PrEP science

Islatravir Subdermal Implant for HIV PrEP Has Promising Phase 1 Trial

Editor's pick
Contagion Live
7 October 2021
Injectable & long-acting HIV treatment

Shionogi licenses out 3rd-gen HIV asset to ViiV

Editor's pick
FierceBiotech
28 September 2021
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Editor's pick
GlobeNewswire
20 September 2021
PrEP science

First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV

Editor's pick
Contagion Live
13 September 2021
New & experimental HIV treatments

CytoDyn’s previous HIV filing snafu now on better course after FDA sets them straight

Editor's pick
Fierce Biotech
16 August 2021
New & experimental HIV treatments

HIV: Could Another Two-Drug Regimen Be on the Horizon?

Editor's pick
Medscape (requires free registration)
21 July 2021
Pharmaceutical industry

Gilead files long-acting HIV med for patients running out of options

Editor's pick
FierceBiotech
1 July 2021
Pharmaceutical industry

GSK puts long-acting injectables at heart of HIV growth plans, downplays threat of oral rival from Gilead and Merck

Editor's pick
FiercePharma
29 June 2021
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Editor's pick
Gilead press release
29 June 2021
Injectable & long-acting HIV treatment

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Editor's pick
Gilead press release
15 March 2021
New & experimental HIV treatments

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Editor's pick
ViiV Healthcare press release
8 February 2021
Injectable & long-acting HIV treatment

FDA approves first long-acting injectable to treat HIV infection

Editor's pick
STAT
22 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Editor's pick
ViiV Healthcare press release
22 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

Editor's pick
ViiV Healthcare press release
21 December 2020
New & experimental HIV treatments

ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Editor's pick
ViiV Healthcare press release
11 December 2020
HIV treatment

Top 10 HIV Clinical Developments of 2020

Editor's pick
TheBodyPro
1 December 2020
New & experimental HIV treatments

Data sets up 2021 filings for Gilead's twice-a-year HIV drug lenacapavir

Editor's pick
Pharmaphorum
20 November 2020
New & experimental HIV treatments

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Editor's pick
Gilead press release
20 November 2020
New & experimental HIV treatments

Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes

Editor's pick
i-Base
9 October 2020
New & experimental HIV treatments

New Long-Acting Injectable HIV Drug Shows Promise in Monkey Study

Editor's pick
POZ
2 September 2020
Pharmaceutical industry

Rival drugmakers' joint trial of medicines for COVID includes an experimental HIV drug

Editor's pick
Thomson Reuters Foundation
4 August 2020
New & experimental HIV treatments

What Are the New HIV Treatment and Prevention Drugs Under Development in 2020?

Editor's pick
TheBodyPro
28 July 2020
New & experimental HIV treatments

FDA spurns CytoDyn's HIV drug because of missing info

Editor's pick
FierceBiotech
14 July 2020
New & experimental HIV treatments

Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

Editor's pick
Dewpoint press release
13 July 2020